Diabetes Obesity & Metabolism

Papers
(The H4-Index of Diabetes Obesity & Metabolism is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
579
248
Diabetes, Obesity and Metabolism223
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”139
Effects of CB1R inverse agonist, INV‐202, in patients with features of metabolic syndrome. A randomized, placebo‐controlled, double‐blind phase 1b study131
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes122
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia104
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c103
Issue Information91
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover91
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis90
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes90
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin86
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease82
Adaptive bolus calculators for people with type 1 diabetes: A systematic review81
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump78
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial78
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’78
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh73
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry73
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa73
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study68
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis65
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study60
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes55
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial55
Long‐term effects of metformin on offspring health: A review of current evidence and future directions54
CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination52
Front Cover52
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity52
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy51
Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment51
The benefit of dexamethasone in patients with COVID‐19 infection is preserved in patients with diabetes48
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial48
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups48
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors48
Disparities in heart failure deaths among people with diabetes in the United States: 1999–202047
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes46
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic46
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes45
Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary ar44
Incidence of chronic kidney disease among adults with prediabetes in the CURE‐CKD registry, 2013–202043
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis42
0.17644691467285